The biological activities of bone cells are regulated by many different factors including specific ligands, some of which are produced locally, and others, for example, calcitonin and parathyroid hormone, which arrive via the circulation. It is likely that the skeletal tissue cells involved in pathological resorption of bone adjacent to the rheumatoid pannus would also be subject to functional modulation by circulating and locally produced ligands. Soluble products released by the pannus 628 bone destruction which characterises the rheumatoid lesion.
Serum levels of parathyroid hormone are normal in patients with rheumatoid arthritis.' 2 Although serum calcitonin levels have been reported to be reduced,2 there is no direct evidence that these low levels contribute to the bone destruction which occurs in patients with rheumatoid disease. We have recently reported that cells cultured from rheumatoid synovium respond to parathyroid hormone and prostaglandin E2 (but not calcitonin) with an increase in cyclic AMP (Fig. 2) . In a time course experiment employing heparin, 1 mg/ml, a biphasic pattern of cyclic AMP content was observed. These changes occurred in cells incubated in buffer alone and in heparin (Fig.  3) . A (Table 2 ). In cultures 1 and 4 salmon calcitonin, 1 ,tg/ml, raised cyclic AMP content 6-fold (Fig. 4) . Incubation of these cultures containing calcitoninresponsive cells with calcitonin, 1 .tg/ml, and heparin, 1 
Discussion
The chronic administration of heparin in high doses to man has been associated with severe osteopenia.7 A similar effect of heparin on enhancing bone resorption has been observed in vitro. Goldhaber,8 employing a mouse calvarial organ culture system, demonstrated that heparin increased bone resorption by potentiating the effects of parathyroid hormone. Our studies were designed to explore the effects of heparin on human trabecular bone cells and to investigate specifically the effects of this mast cell product on the response of the target cells to hormones which are known to regulate skeletal tissue homoeostasis.
To study the effects of heparin on cells of skeletal origin we have cultured cells from human bone. An early feature of trabecular bone explants was active cellular activity at the surfaces of the explant which preceded the appearance of bone-derived cells adherent to the plate. Examination with phase contrast microscopy revealed that these surface cells appeared to be synthesising an extracellular matrix, consistent with the proposal that osteoblast-like cells were cultured by this method. 1 The presence of a cyclic AMP response to parathyroid hormone in four out of our eight bone cell cultures further suggests that the outgrowth cells express osteoblast phenotype. 15 These cells also show strongly positive staining for alkaline phosphatase,16 17 which -with parathyroid hormone responsiveness -has been considered a marker of osteoblast-like cells isolated from non-human skeletal tissues.18
We observed that heparin glycosaminoglycan increased the intracellular content of cyclic AMP in a dose-dependent manner in cultured human trabecular bone cells. The interactions of calcitonin, parathyroid hormone, and prostaglandins with their cell surface receptors are accompanied by activation of adenylate cyclase and rises in intracellular cyclic AMP, and at least some of the biological effects of these hormones are probably mediated by changes in levels of this cyclic nucleotide. It There are precedents for an inhibitory role of heparin on hormone action. Heparin has been shown to inhibit luteinising-hormone-stimulated ovarian adenylate cyclase.'9 Dextran sulphate, the polyanion analogue of heparin, inhibits adenylate cyclase in bovine thyroid preparations. 20 The mechanism of inhibition is unknown. Wolff and Cook20 considered the possibility that the large negative charge of these polyelectrolytes could alter cell membrane function. Structural features other than ionic charge could be important, since the equally negatively charged polyglutamic acid was only slightly inhibitory of ovarian adenylate cyclase. '9 It has recently been shown that heparin can suppress the cumulus cell-oocyte complex expansion in mice which is mediated by follicle stimulating hormone but does not do so by the inhibition of cyclic AMP production.2 ' We also report that heparin increases intracellular cyclic AMP content in adherent rheumatoid synovial cells. We have demonstrated that these cells produce large amounts of prostaglandin E2 and collagenase, products implicated in pathological bone resorption. The possible role of cyclic AMP in modulating release of these products is not known. Although we have demonstrated that parathyroid hormone increases cyclic AMP content in synovial cells, we have not so far detected effects of this hormone on prostaglandin or collagenase production (Goldring SR, Dayer JM, Krane SM, personal communication). The framework of mast cell granules is the metachromatic-staining heparin proteoglycan, and it has been recently reported that rat fibroblasts which ingest extruded mast cell granules increase their own production of collagenase. 24 It is possible that this could be mediated by cyclic AMP in the light of reports that cyclic AMP production may influence other secretory functions of human monocytes.25 We have not yet assayed the effects of heparin on collagenase production by synovial cells.
An increase in cyclic AMP content of bone and synovial cells exposed to heparin was observed within 5-10 minutes followed by a later further increase. It is likely that the early peak of production at 5-10 minutes is associated with cellular effects of cyclic AMP 
